Literature DB >> 21613350

Growth hormone (GH)-induced insulin resistance is rapidly reversible: an experimental study in GH-deficient adults.

T Krusenstjerna-Hafstrøm1, B F Clasen, N Møller, N Jessen, S B Pedersen, J S Christiansen, J O L Jørgensen.   

Abstract

CONTEXT: It is clinically relevant and of physiological interest to investigate whether GH-induced insulin resistance depends on the timing of GH exposure relative to when insulin sensitivity is assessed. HYPOTHESIS: GH-induced insulin resistance is rapidly reversible. DESIGN AND PARTICIPANTS: Eight male GH-deficient patients underwent a 6-h euglycemic-hyperinsulinemic glucose clamp thrice in a randomized crossover design receiving either no GH (study 0), a 7-h GH infusion (0.2-0.3 mg in total) that terminated 5 h before the clamp (study 1), or a similar GH infusion timed to continue during the first hour of the clamp (study 2). A muscle biopsy was obtained 30 min into the clamp. The patients were compared with eight healthy untreated control subjects (study c). MAIN OUTCOME MEASURES: The glucose infusion rate, indirect calorimetry, and free fatty acid metabolism were assessed. In muscle biopsies, protein phosphorylation of signal transducer and activator of transcription 5, Akt, and Akt substrate 160 (phospho-Akt substrate signal) and gene expression of IGF-I and SOCS1-3 were assessed.
RESULTS: Insulin sensitivity differed significantly between the GH-deficiency studies (P = 0.005) with distinct insulin resistance in study 2 and increased insulin sensitivity in study 0 [area under the glucose infusion rate curve (mg/kg · min): 1663 ± 151 (study 0) vs. 1482 ± 166 (study 1) vs. 1123 ± 136 (study 2) vs. 1492 ± 229 (control group)]. Free fatty acid levels and lipid oxidation were elevated in response to GH exposure but became suppressed during the clamp. IGF-I and SOCS3 gene expression was increased in study 2.
CONCLUSIONS: Very-low-dose GH exposure evokes acute insulin resistance that subsides after 5 h. This time-dependent reversibility should be considered when assessing the impact of GH on glucose homeostasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21613350     DOI: 10.1210/jc.2011-0273

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  19 in total

1.  Effects of GH in women with abdominal adiposity: a 6-month randomized, double-blind, placebo-controlled trial.

Authors:  Miriam A Bredella; Eleanor Lin; Danielle J Brick; Anu V Gerweck; Lindsey M Harrington; Martin Torriani; Bijoy J Thomas; David A Schoenfeld; Anne Breggia; Clifford J Rosen; Linda C Hemphill; Zida Wu; Nader Rifai; Andrea L Utz; Karen K Miller
Journal:  Eur J Endocrinol       Date:  2012-01-24       Impact factor: 6.664

2.  Growth hormone controls lipolysis by regulation of FSP27 expression.

Authors:  Rita Sharma; Quyen Luong; Vishva M Sharma; Mitchell Harberson; Brian Harper; Andrew Colborn; Darlene E Berryman; Niels Jessen; Jens Otto Lunde Jørgensen; John J Kopchick; Vishwajeet Puri; Kevin Y Lee
Journal:  J Endocrinol       Date:  2018-12-01       Impact factor: 4.286

3.  Differential impact of selective GH deficiency and endogenous GH excess on insulin-mediated actions in muscle and liver of male mice.

Authors:  Jose Cordoba-Chacon; Manuel D Gahete; Owen P McGuinness; Rhonda D Kineman
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-09-30       Impact factor: 4.310

4.  Effects of growth hormone withdrawal in obese premenopausal women.

Authors:  E Lin; M A Bredella; A V Gerweck; M Landa; D Schoenfeld; A L Utz; K K Miller
Journal:  Clin Endocrinol (Oxf)       Date:  2013-06       Impact factor: 3.478

5.  Relationship between serum circulating insulin-like growth factor-1 and liver fat in the United States.

Authors:  Shauna S Runchey; Edward J Boyko; George N Ioannou; Kristina M Utzschneider
Journal:  J Gastroenterol Hepatol       Date:  2014-03       Impact factor: 4.029

6.  Effects of GH on body composition and cardiovascular risk markers in young men with abdominal obesity.

Authors:  Miriam A Bredella; Anu V Gerweck; Eleanor Lin; Melissa G Landa; Martin Torriani; David A Schoenfeld; Linda C Hemphill; Karen K Miller
Journal:  J Clin Endocrinol Metab       Date:  2013-07-03       Impact factor: 5.958

7.  Recombinant human growth hormone in treatment of diabetes: report of three cases and review of relative literature.

Authors:  Dandan Wang; Naicheng Zhao; Ziyang Zhu
Journal:  Int J Clin Exp Med       Date:  2015-05-15

8.  Gene expression in skeletal muscle after an acute intravenous GH bolus in human subjects: identification of a mechanism regulating ANGPTL4.

Authors:  Berthil F F Clasen; Thomas Krusenstjerna-Hafstrøm; Mikkel Holm Vendelbo; Kasper Thorsen; Carlos Escande; Niels Møller; Steen B Pedersen; Jens Otto L Jørgensen; Niels Jessen
Journal:  J Lipid Res       Date:  2013-04-20       Impact factor: 5.922

Review 9.  Effect of growth hormone on insulin signaling.

Authors:  Rita Sharma; John J Kopchick; Vishwajeet Puri; Vishva M Sharma
Journal:  Mol Cell Endocrinol       Date:  2020-09-20       Impact factor: 4.102

10.  Short-term, low-dose GH therapy improves insulin sensitivity without modifying cortisol metabolism and ectopic fat accumulation in adults with GH deficiency.

Authors:  Kevin C J Yuen; Charles T Roberts; Jan Frystyk; William D Rooney; James R Pollaro; Bethany J Klopfenstein; Jonathan Q Purnell
Journal:  J Clin Endocrinol Metab       Date:  2014-07-11       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.